ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Mass. Requires Coverage of Routine Patient Care In Clinical Trials

September 6, 2002

Grant Supplements, and Challenge Grants

February 20, 2009

PDF file includes 8-page February issue of Business & Regulatory Report.

February 27, 2004

VTP Implementing 95% Of Ad Hoc Panel Suggestions

May 10, 1985

Isis 3521 Gets Fast-track Status For FDA Review.

December 1, 2000

FDA Didn’t Tell Advisors About Data Linking Obesity Drug With Precancerous Lesions.

June 2, 2006